Originally posted by Nanoporous
View Post
Unconfigured Ad
Collapse
X
-
I agree. After what happened with PacBio and Helicos (should I dare to say disappointment) the scientific community is much more careful now. That doesn’t mean ONT will not deliver, but until they can show real evidence of what they claimed, they will be seen with suspicion.
-
-
GenoMax/larissa
Be aware Illumina also made an $18 million investment in Oxford Nanopore when they entered a strategic alliance in January 2009.
Comment
-
-
ians - No lamda data yet, so far as I am aware, although the company did raise another $50m or so recently from existing shareholders. http://www.nanoporetech.com/news/press-releases/view/40
Comment
-
-
Hey all,
Interesting to read in the whole thread though I'm not really able to participate since I just recently joined the Seq community. So could anyone give me a short summary of what happened with the different platforms and how the market is developing at the moment? There has been so much going on that I lost track completely compared to what we were told during my studies (which was mainly focussing on the different techniques).
In short: who is still in business and which techniques survived so far?
Cheers
Comment
-
-
Illumina: Market leader.Originally posted by rboettcher View PostHey all,
Interesting to read in the whole thread though I'm not really able to participate since I just recently joined the Seq community. So could anyone give me a short summary of what happened with the different platforms and how the market is developing at the moment? There has been so much going on that I lost track completely compared to what we were told during my studies (which was mainly focussing on the different techniques).
In short: who is still in business and which techniques survived so far?
Cheers
Life: Could become market leader with their Proton sequencer in the near future.
Oxford Nanopore: Super cool technology but seriously lacks credibility. Remains to be seen whether they can live up to their promises.
The rest: Might be intesting in 5+ years or failed already.
Comment
-
-
454 used to be a viable option for certain appications, but nobody in their right mind would buy one of their sequencers today. Not with Illumina and Ion Torrent approaching 400 bp reads.
Helicos is pretty much dead.
PacBio is still alive and possibly intersting for niche appication but unlikely be able to survive on that.
Comment
-
-
Availability?
Does anyone have any info as to the date of commercial availability of the MinION?
Back in february they said 6-9 months, but not a peep since.
As a matter of fact, has anyone seen one of these in the wild? or anywhere for that matter?
Comment
-
-
Okay, this is anecdotal, but my wife was at an NIH awardees meeting in Washington a few months ago. This was for an education grant. One of the plenary speakers was Francis Collins. During his talk he held up a device about the size of a thumb drive and made some comments about the rapid progress of sequencing.
The weird thing was that he referred to this device as an Ion Torrent. But after the talk, as he was leaving the room, my wife asked him -- is than a MinIon? And he said that it was.
--
Phillip
Comment
-
-
Yeah, who knows if that was a live MinIon. Could have been, but it also could have been a mock-up given him by ONT. Or a random thumb drive. Also I wasn't there and this was a talk given to an audience not expert in sequencing tech. So he may just have been trying to make a point. Or meant something else...
--
Phillip
Comment
-
Latest Articles
Collapse
-
by SEQadmin2
Data variability is still an issue in sequencing technologies despite the advances in reproducibility and accuracy of these platforms. But the problem does not originate in the sequencing itself, but in the previous steps, before the sample reaches the sequencer.
The first step is collection, followed by preservation and sample preparation for analysis. Most scientists overlook those steps, but not being careful might just be skewing the experiment’s results.
...-
Channel: Articles
06-02-2026, 10:05 AM -
-
by SEQadmin2
With the launch of new single-cell sequencing platforms in 2026, the field stands at an exciting inflection point. This article surveys the most impactful advances in the field and discusses how they’re reshaping research in cancer, immunology, and beyond.
Introduction
Single-cell sequencing technologies have undergone remarkable advances over the past decade, transitioning from low-throughput experimental approaches to highly scalable platforms capable of...-
Channel: Articles
05-22-2026, 06:42 AM -
ad_right_rmr
Collapse
News
Collapse
| Topics | Statistics | Last Post | ||
|---|---|---|---|---|
|
Sequencing the Two-Toed Sloth Genome Reveals Jumping Genes Tied to Its Extreme Metabolism
by SEQadmin2
Started by SEQadmin2, Yesterday, 11:58 AM
|
0 responses
10 views
0 reactions
|
Last Post
by SEQadmin2
Yesterday, 11:58 AM
|
||
|
Started by SEQadmin2, 06-05-2026, 10:09 AM
|
0 responses
25 views
0 reactions
|
Last Post
by SEQadmin2
06-05-2026, 10:09 AM
|
||
|
Started by SEQadmin2, 06-04-2026, 08:59 AM
|
0 responses
35 views
0 reactions
|
Last Post
by SEQadmin2
06-04-2026, 08:59 AM
|
||
|
Started by SEQadmin2, 06-02-2026, 12:03 PM
|
0 responses
59 views
0 reactions
|
Last Post
by SEQadmin2
06-02-2026, 12:03 PM
|

Comment